Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

62.06EUR
22 May 2017
Change (% chg)

-- (--)
Prev Close
€62.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,589
52-wk High
€70.92
52-wk Low
€45.05

DBV.PA

Chart for DBV.PA

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.50
Market Cap(Mil.): €1,519.74
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 14.32 17.37
EPS (TTM): -4.67 -- --
ROI: -39.11 -7.73 -5.89
ROE: -40.55 -7.36 -5.30

BRIEF-Dbv Technologies cash position shrinks to EUR 227.0 mln

* Cash and cash equivalents amounted to EUR 227.0 million ($246.5 million) as of March 31, 2017 compared to EUR 256.5 million as of Dec 31, 2016 Source text for Eikon: Further company coverage: ($1 = 0.9207 euros) (Gdynia Newsroom)

Apr 28 2017

BRIEF-DBV Technologies FY net loss widens to 114.5 mln euros

* FY net loss of amounts to 114.5 million euros versus a loss of 44.7 million euros a year ago

Mar 15 2017

BRIEF-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children

* Reg-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children

Mar 10 2017

BRIEF-DBV Technologies cash and cash equivalents down at 256.5 million euros as of December 31, 2016

* DBV’s cash and cash equivalents amounted to 256.5 million euros ($272.0 million) as of december 31, 2016, compared to 323.4 million euros as of December 31, 2015. Source text for Eikon: Further company coverage: ($1 = 0.9430 euros) (Gdynia Newsroom)

Feb 20 2017

BRIEF-DBV Technologies completes enrollment phase IIa viaskin milk study for of pediatric eosinophilic esophagitis

* DBV Technologies announces completion of enrollment of phase IIa study of viaskin milk for the treatment of pediatric eosinophilic esophagitis

Feb 03 2017

More From Around the Web

Earnings vs. Estimates